An Investigation on the Role of Emergency Departments in Combatting Against COVID-19 in Zhejiang Province
July 15, 2021 updated by: Second Affiliated Hospital, School of Medicine, Zhejiang University
The epidemic caused by the new coronavirus appeared in December 2019 and spread rapidly, and it has had a serious impact on the social development and people's lives in the world.
On February 11, 2020, the World Health Organization (WHO) named the infectious disease caused by the virus COVID-19.
my country classifies it as a Class B infectious disease, and controls it as a Class A infectious disease.
In order to effectively respond to the epidemic, on January 23, 2020, Zhejiang Province first launched a first-level response to major public health emergencies across the country.
Some patients with new coronary pneumonia, especially critically ill patients, may go to the emergency department first.
Emergency medical staff must identify and isolate patients with new coronary pneumonia in a timely manner while ensuring the treatment of critically ill patients.
People face greater unknowns and challenges in the anti-epidemic work.
this research Participating in the prevention and control of the new crown pneumonia epidemic through investigations in the emergency department of Zhejiang Province Related conditions, to further improve the hospital's emergency medical service capabilities for reference.
Study Overview
Status
Completed
Conditions
Detailed Description
References：
- Huang CL, Wang YM, Li XW, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet, 2020, 395(10223): 497-506. DOI:10.1016/s0140-6736(20)30183-5.
- Zhu N, Zhang DY, Wang WL, et al. A novel coronavirus from patients with pneumonia in China, 2019[J]. N Engl J Med, 2020, 382(8): 727- 733. DOI:10.1056/nejmoa2001017.
- Gupta M, Abdelmaksoud A, Jafferany M, et al. COVID-19 and economy[J]. Dermatol Ther, 2020: e13329. DOI:10.1111/dth.13329.
- Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome- related coronavirus: classifying 2019-nCoV and naming it SARS- CoV-2 [J]. Nat Microbiol, 2020, 5(4):536-544. DOI:10.1038/s41564- 020-0695-z.
- Lai CC, Shih TP, Ko WC, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges[J]. Int J Antimicrob Agents, 2020, 55(3): 105924. DOI:10.1016/j.ijantimicag.2020.105924.
Study Type
Observational
Enrollment (Actual)
181
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310009
- Second Affiliated Hospital, Zhejiang University School of Medicine & Institute of Emergency Medicine, Zhejiang University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Not applicable, not included in patients
Description
Inclusion Criteria:
- County-level people's hospitals, TCM hospitals and above comprehensive public hospitals in Zhejiang Province;
- Voluntary participation in this study.
Exclusion Criteria:
- Incomplete data
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Basic information of the hospital
Time Frame: 7 day
|
Hospital level, whether it is a designated hospital for COVID-19, whether it is capable of detecting nucleic acid for the new coronavirus, whether it has a fever clinic
|
7 day
|
|
Participation of the emergency department in fever clinics
Time Frame: 7 day
|
The department/department responsible for the management of the fever clinic, whether the medical staff of the fever clinic has a fixed establishment, and the medical staff that temporarily supports the fever clinic source department
|
7 day
|
|
Patients with COVID-19 admitted to the emergency department
Time Frame: 7 day
|
Number and distribution of patients
|
7 day
|
|
The frontline situation of emergency medical care support in the fight against the epidemic
Time Frame: 7 day
|
Support the fever clinic of this hospital, isolation observation ward/confirmed ward, participate in the prehospital/inter-hospital transfer of new crown cases, participate in the hospital/regional prevention and management expert group, support the ward/ICU of designated hospitals in the province, support the ward of Hubei Province /ICU/ Fangcang shelter hospital
|
7 day
|
|
Epidemic prevention facilities in the emergency department
Time Frame: 7 day
|
Number of spare separate consultation rooms, ordinary rescue rooms, and negative pressure rescue rooms, the supply of early anti-epidemic protective equipment
|
7 day
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
March 9, 2020
Primary Completion (ACTUAL)
March 15, 2020
Study Completion (ACTUAL)
March 30, 2020
Study Registration Dates
First Submitted
May 29, 2021
First Submitted That Met QC Criteria
June 4, 2021
First Posted (ACTUAL)
June 7, 2021
Study Record Updates
Last Update Posted (ACTUAL)
July 22, 2021
Last Update Submitted That Met QC Criteria
July 15, 2021
Last Verified
March 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2020-292
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19 Pneumonia
-
Ministry of Health, KuwaitUnknownPneumonia, Viral | Moderate COVID-19 Pneumonia, Severe COVID-19 PneumoniaKuwait
-
Institute of Vaccines and Medical Biologicals,...National Institute of Hygiene and Epidemiology, Vietnam; Hanoi Medical University and other collaboratorsCompletedPneumonia, Viral | COVID-19 Vaccine | COVID-19 Disease | SARS PneumoniaVietnam
-
Patrick RobinsonRecruitingCovid19 | COVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Acute BronchitisUnited States
-
Mahidol UniversityThe Government Pharmaceutical OrganizationCompletedPneumonia, Viral | Covid-19 | SARS Pneumonia | Covid-19 VaccineThailand
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
Fundacion Clinica Valle del LiliUniversidad Autonoma de OccidenteCompletedCOVID-19 Pneumonia | COVID-19 (Coronavirus Disease 2019)Colombia
-
Medical University of LodzRecruitingCOVID-19 | COVID-19 Pneumonia | COVID-19 Respiratory InfectionPoland
-
Texas Tech University Health Sciences Center, El...RecruitingPneumonia, Viral | COVID-19 Pneumonia | COVID-19 Respiratory InfectionUnited States
-
Administracion Nacional de Laboratorios e Institutos...RecruitingCovid19 | COVID-19 Pneumonia | COVID-19 Respiratory InfectionArgentina
-
Fondazione Policlinico Universitario Agostino Gemelli...CompletedCovid19 | COVID-19 Pneumonia | COVID-19 Respiratory InfectionItaly